![](/images/graphics-bg.png)
Chronic Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Decreases Hypertension, Insulin Resistance, and Hypertriglyceridemia in Metabolic Syndrome
Joint Authors
Schnackenberg, Christine G.
Costell, Melissa H.
Krosky, Daniel J.
Cui, Jianqi
Wu, Charlene W.
Hong, Victor S.
Harpel, Mark R.
Willette, Robert N.
Yue, Tian-Li
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-03-17
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Metabolic syndrome is a constellation of risk factors including hypertension, dyslipidemia, insulin resistance, and obesity that promote the development of cardiovascular disease.
Metabolic syndrome has been associated with changes in the secretion or metabolism of glucocorticoids, which have important functions in adipose, liver, kidney, and vasculature.
Tissue concentrations of the active glucocorticoid cortisol are controlled by the conversion of cortisone to cortisol by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
Because of the various cardiovascular and metabolic activities of glucocorticoids, we tested the hypothesis that 11β-HSD1 is a common mechanism in the hypertension, dyslipidemia, and insulin resistance in metabolic syndrome.
In obese and lean SHR/NDmcr-cp (SHR-cp), cardiovascular, metabolic, and renal functions were measured before and during four weeks of administration of vehicle or compound 11 (10 mg/kg/d), a selective inhibitor of 11β-HSD1.
Compound 11 significantly decreased 11β-HSD1 activity in adipose tissue and liver of SHR-cp.
In obese SHR-cp, compound 11 significantly decreased mean arterial pressure, glucose intolerance, insulin resistance, hypertriglyceridemia, and plasma renin activity with no effect on heart rate, body weight gain, or microalbuminuria.
These results suggest that 11β-HSD1 activity in liver and adipose tissue is a common mediator of hypertension, hypertriglyceridemia, glucose intolerance, and insulin resistance in metabolic syndrome.
American Psychological Association (APA)
Schnackenberg, Christine G.& Costell, Melissa H.& Krosky, Daniel J.& Cui, Jianqi& Wu, Charlene W.& Hong, Victor S.…[et al.]. 2013. Chronic Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Decreases Hypertension, Insulin Resistance, and Hypertriglyceridemia in Metabolic Syndrome. BioMed Research International،Vol. 2013, no. 2013, pp.1-10.
https://search.emarefa.net/detail/BIM-1004290
Modern Language Association (MLA)
Schnackenberg, Christine G.…[et al.]. Chronic Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Decreases Hypertension, Insulin Resistance, and Hypertriglyceridemia in Metabolic Syndrome. BioMed Research International No. 2013 (2013), pp.1-10.
https://search.emarefa.net/detail/BIM-1004290
American Medical Association (AMA)
Schnackenberg, Christine G.& Costell, Melissa H.& Krosky, Daniel J.& Cui, Jianqi& Wu, Charlene W.& Hong, Victor S.…[et al.]. Chronic Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Decreases Hypertension, Insulin Resistance, and Hypertriglyceridemia in Metabolic Syndrome. BioMed Research International. 2013. Vol. 2013, no. 2013, pp.1-10.
https://search.emarefa.net/detail/BIM-1004290
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1004290